Arcturus Therapeutics Holdings Inc. (ARCT)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous Close | 25.31 |
| Open | 24.99 |
| Bid | 23.70 x 900 |
| Ask | 24.66 x 1400 |
| Day's Range | 24.59 - 26.25 |
| 52 Week Range | 24.57 - 89.18 |
| Volume | |
| Avg. Volume | 612,830 |
| Market Cap | 648.205M |
| Beta (5Y Monthly) | 2.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.55 |
| Earnings Date | Feb. 28, 2022 - Mar. 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 85.45 |
- Business Wire
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, January 22, 2022--Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new member of the Board of Directors. Dr. Marantz is an experienced biopharmaceutical industry executive who has held senior level positions in medical affairs, business development, and commercial strategy in multiple therapeutic areas, includin
- Simply Wall St.
While Arcturus Therapeutics Holdings (NASDAQ:ARCT) shareholders have made 872% in 3 years, increasing losses might now be front of mind as stock sheds 15% this week
It hasn't been the best quarter for Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders, since the share...
